Inhibition of serotonin synthesis: A novel therapeutic paradigm

摘要: The rate-limiting enzyme in serotonin synthesis is tryptophan hydroxylase (TPH). There are two independent systems the body characterized by isoforms of TPH, TPH1 and TPH2. While TPH2 synthesizes brain, expressed gut other peripheral tissues supplies platelets circulation with serotonin. This duality system enforced blood-brain barrier which impermeable for In brain acts as neurotransmitter a main target treatment psychiatric disorders. periphery it released at site activation elicits numerous physiological effects. deficient mice were shown to be protected from diverse diseases including hemostatic, inflammatory, fibrotic, gastrointestinal, metabolic disorders therefore inhibition emerged reasonable therapeutic paradigm. Recently first TPH inhibitor, telotristat ethyl, came on market carcinoid syndrome. review summarizes state development opportunities such compounds.